A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Inclusion Criteria:
Exclusion Criteria:
Hyattsville, Maryland 20782, United States
Troy, Michigan 48098, United States
Wenatchee, Washington 98801, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires 1414, Argentina
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
C.a.b.a., Buenos Aires F.D. C1205AAO, Argentina
CABA, Buenos Aires F.D. 1204, Argentina
Godoy Cruz, Mendoza Province 5501, Argentina
Mexico City, Mexico City 11650, Mexico